{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:11:32Z","timestamp":1775038292107,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Seit dem 1.\u00a0M\u00e4rz 2017 ist medizinisches Cannabis (MC) bundesweit verschreibungsf\u00e4hig. Zur Wirksamkeit von MC bei Fibromyalgiesyndrom (FMS) existieren bisher einige qualitativ unterschiedliche Studien.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Ziel der Untersuchung war, die Wirksamkeit von Tetrahydrocannabinol (THC) im Verlauf einer IMST hinsichtlich des Schmerzes und mehrerer psychometrischer Variablen zu untersuchen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>F\u00fcr die Studie wurden im Studienzeitraum (2017\u20132018) alle Patienten einer Schmerzstation, die an einem FMS erkrankt waren und in einem multimodalen, interdisziplin\u00e4ren Setting behandelt wurden, entsprechend den Einschlusskriterien selektioniert. Die Patienten wurden getrennt nach Gruppen mit und ohne THC-Medikation bzgl. der Schmerzintensit\u00e4t, verschiedener psychometrischer Parameter und des Analgetikaverbrauchs w\u00e4hrend des Aufenthalts untersucht.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Von den 120 in die Studie eingeschlossenen FMS-Patienten wurden 62\u00a0Patienten (51,7\u202f%) mit THC behandelt. In den Parametern Schmerzintensit\u00e4t, Depressivit\u00e4t und Lebensqualit\u00e4t zeigte sich eine signifikante Besserung der Gesamtgruppe w\u00e4hrend des Aufenthalts (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090,001), die durch den Einsatz von THC signifikant st\u00e4rker ausfiel. In f\u00fcnf der sieben untersuchten Analgetikagruppen konnte bei den mit THC behandelten Patienten signifikant h\u00e4ufiger die Dosis reduziert bzw. das Medikament abgesetzt werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die Ergebnisse liefern Hinweise daf\u00fcr, dass THC als medikament\u00f6se Alternative in Erg\u00e4nzung zu den bisher in verschiedenen Leitlinien empfohlenen Substanzen f\u00fcr die Therapie des FMS in Betracht gezogen werden kann.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00482-023-00727-4","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T14:02:34Z","timestamp":1686232954000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tetrahydrocannabinol (THC) bei\u00a0Patienten mit Fibromyalgiesyndrom (FMS)","Tetrahydrocannabinol (THC) in patients with fibromyalgia syndrome (FMS)"],"prefix":"10.1007","volume":"38","author":[{"given":"Horst","family":"Bettstetter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"727_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","volume":"49","author":"R Abuhasira","year":"2018","unstructured":"Abuhasira\u00a0R, Shbiro\u00a0L, Landschaft\u00a0Y (2018) Medical use of cannabis and cannabinoids containing products\u2014Regulations in Europe and North America. Eur J Intern Med 49:2\u20136","journal-title":"Eur J Intern Med"},{"key":"727_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/pm\/pnaa303","volume":"21","author":"C Chaves","year":"2020","unstructured":"Chaves\u00a0C, Bittencourt\u00a0PCT, Pelegrini\u00a0A (2020) Ingestion of a\u00a0THC-rich cannabis oil in people with fibromyalgia: a randomized, double-blind, placebo-controlled clinical trial. Pain Med 21:2212\u20132218","journal-title":"Pain Med"},{"issue":"Suppl 123","key":"727_CR3","first-page":"53","volume":"38","author":"V Giorgi","year":"2020","unstructured":"Giorgi\u00a0V, Bongiovanni\u00a0S, Atzeni\u00a0F et\u00a0al (2020) Adding medical cannabis to standard analgesic treatment for fibromyalgia: a\u00a0prospective observational study. Clin Exp Rheumatol 38(Suppl 123):53\u201359","journal-title":"Clin Exp Rheumatol"},{"key":"727_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/978-3-642-55125-3_39","volume-title":"Handbuch Psychoaktive Substanzen","author":"F Grotenhermen","year":"2018","unstructured":"Grotenhermen\u00a0F (2018) Endogene Cannabinoide und das Endocannabinoidsystem. In: Handbuch Psychoaktive Substanzen, S\u00a0411\u2013420"},{"key":"727_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/RHU.0000000000000702","volume":"24","author":"G Habib","year":"2018","unstructured":"Habib\u00a0G, Artul\u00a0S (2018) Medical cannabis for the treatment of fibromyalgia. J\u00a0Clin Rheumatol 24:255\u2013258","journal-title":"J Clin Rheumatol"},{"key":"727_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","volume":"42","author":"C Herrmann","year":"1997","unstructured":"Herrmann\u00a0C (1997) International experiences with the Hospital Anxiety and Depression Scale\u2014a review of validation data and clinical results. J\u00a0Psychosom Res 42:17\u201341","journal-title":"J Psychosom Res"},{"key":"727_CR7","doi-asserted-by":"publisher","unstructured":"Hryhorowicz S, Kaczmarek-Rys M, Andrzejewska A et al (2019) Allosteric modulation of cannabinoid receptor 1\u2011current challenges and future opportunities. Int J Mol Sci 20:5874. https:\/\/doi.org\/10.3390\/ijms20235874","DOI":"10.3390\/ijms20235874"},{"key":"727_CR8","unstructured":"International Association for the Study of Pain (Iasp) (2022) Terminology. https:\/\/www.iasp-pain.org\/resources\/terminology. Zugegriffen: 15. Nov. 2022"},{"key":"727_CR9","first-page":"e17332","volume":"13","author":"H Khurshid","year":"2021","unstructured":"Khurshid\u00a0H, Qureshi\u00a0IA, Jahan\u00a0N et\u00a0al (2021) A systematic review of fibromyalgia and recent advancements in treatment: is medicinal cannabis a\u00a0new hope? Cureus 13:e17332","journal-title":"Cureus"},{"key":"727_CR10","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000507","volume":"157","author":"E Kosek","year":"2016","unstructured":"Kosek\u00a0E, Cohen\u00a0M, Baron\u00a0R et\u00a0al (2016) Do we need a\u00a0third mechanistic descriptor for chronic pain states? Pain 157:1382\u20131386","journal-title":"Pain"},{"key":"727_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12954-020-00377-0","volume":"17","author":"N Lintzeris","year":"2020","unstructured":"Lintzeris\u00a0N, Mills\u00a0L, Suraev\u00a0A et al (2020) Medical cannabis use in the Australian community following introduction of legal access: the 2018\u20132019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct\u00a0J 17:37","journal-title":"Harm Reduct J"},{"key":"727_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA Maccallum","year":"2018","unstructured":"Maccallum\u00a0CA, Russo\u00a0EB (2018) Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 49:12\u201319","journal-title":"Eur J Intern Med"},{"key":"727_CR13","doi-asserted-by":"publisher","first-page":"e1916015","DOI":"10.1001\/jamanetworkopen.2019.16015","volume":"2","author":"BK Madras","year":"2019","unstructured":"Madras\u00a0BK, Han\u00a0B, Compton\u00a0WM et\u00a0al (2019) Associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse. Jama Netw Open 2:e1916015","journal-title":"Jama Netw Open"},{"key":"727_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s42238-021-00060-6","volume":"3","author":"M Mazza","year":"2021","unstructured":"Mazza\u00a0M (2021) Medical cannabis for the treatment of fibromyalgia syndrome: a\u00a0retrospective, open-label case series. J\u00a0Cannabis Res 3:4","journal-title":"J Cannabis Res"},{"key":"727_CR15","doi-asserted-by":"publisher","first-page":"908610","DOI":"10.1155\/2013\/908610","volume":"2013","author":"A Michalsen","year":"2013","unstructured":"Michalsen\u00a0A, Li\u00a0C, Kaiser\u00a0K et al (2013) In-patient treatment of fibromyalgia: a controlled nonrandomized comparison of conventional medicine versus integrative medicine including fasting therapy. Evid Based Complement Alternat Med 2013:908610","journal-title":"Evid Based Complement Alternat Med"},{"key":"727_CR16","volume-title":"Handbuch zum Deutschen Schmerzfragebogen","author":"MNB Pfingsten","year":"2007","unstructured":"Pfingsten\u00a0MNB, Emrich\u00a0O (2007) Handbuch zum Deutschen Schmerzfragebogen"},{"key":"727_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s004820050003","volume":"14","author":"M Pfingsten","year":"2000","unstructured":"Pfingsten\u00a0M, Schops\u00a0P, Wille\u00a0T et\u00a0al (2000) Classification of chronic pain. Quantification and grading with the Mainz Pain Staging System. Schmerz 14:10\u201317","journal-title":"Schmerz"},{"key":"727_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","volume":"17","author":"LP Queiroz","year":"2013","unstructured":"Queiroz\u00a0LP (2013) Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 17:356","journal-title":"Curr Pain Headache Rep"},{"key":"727_CR19","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1093\/pm\/pnaa163","volume":"21","author":"R Safakish","year":"2020","unstructured":"Safakish\u00a0R, Ko\u00a0G, Salimpour\u00a0V et\u00a0al (2020) Medical cannabis for the management of pain and quality of life in chronic pain patients: a prospective observational study. Pain Med 21:3073\u20133086","journal-title":"Pain Med"},{"key":"727_CR20","doi-asserted-by":"publisher","unstructured":"Sagy I, Bar-Lev Schleider L, Abu-Shakra M et al (2019) Safety and efficacy of medical cannabis in fibromyalgia. J\u00a0Clin Med 8:807. https:\/\/doi.org\/10.3390\/jcm8060807","DOI":"10.3390\/jcm8060807"},{"key":"727_CR21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1185\/030079906X112651","volume":"22","author":"M Schley","year":"2006","unstructured":"Schley\u00a0M, Legler\u00a0A, Skopp\u00a0G et al (2006) Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 22:1269\u20131276","journal-title":"Curr Med Res Opin"},{"key":"727_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek\u00a0RQ, Galimova\u00a0L, Ethans\u00a0K et\u00a0al (2008) Nabilone for the treatment of pain in fibromyalgia. J\u00a0Pain 9:164\u2013173","journal-title":"J Pain"},{"key":"727_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00482-017-0207-0","volume":"31","author":"C Sommer","year":"2017","unstructured":"Sommer\u00a0C, Alten\u00a0R, Bar\u00a0KJ et\u00a0al (2017) Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles. Schmerz 31:274\u2013284","journal-title":"Schmerz"},{"key":"727_CR24","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41598-019-39462-1","volume":"9","author":"SS Stith","year":"2019","unstructured":"Stith\u00a0SS, Vigil\u00a0JM, Brockelman\u00a0F et\u00a0al (2019) The association between cannabis product characteristics and symptom relief. Sci Rep 9:2712","journal-title":"Sci Rep"},{"key":"727_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T Van De Donk","year":"2019","unstructured":"Van De Donk\u00a0T, Niesters\u00a0M, Kowal\u00a0MA et al (2019) An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 160:860\u2013869","journal-title":"Pain"},{"key":"727_CR26","doi-asserted-by":"publisher","unstructured":"Weber J, Schley M, Casutt M et al (2009) Tetrahydrocannabinol (delta 9\u2011THC) treatment in chronic central Neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiol Res Pract 2009:827290. https:\/\/doi.org\/10.1155\/2009\/827290","DOI":"10.1155\/2009\/827290"},{"key":"727_CR27","doi-asserted-by":"publisher","unstructured":"Yassin M, Garti A, Robinson D (2016) Effect of medicinal cannabis therapy (MCT) on severity of chronic low back pain, sciatica and lumbar range of motion. Int J Anesthesiol Pain Med 02. https:\/\/doi.org\/10.21767\/2471-982X.100014","DOI":"10.21767\/2471-982X.100014"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-023-00727-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-023-00727-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-023-00727-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T07:06:10Z","timestamp":1721372770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-023-00727-4"}},"subtitle":["Retrospektive Untersuchung zu Ver\u00e4nderungen von Schmerz, psychometrischen Variablen und Analgetikaverbrauch im Verlauf einer interdisziplin\u00e4ren multimodalen station\u00e4ren Schmerztherapie (IMST)","A retrospective study of changes in pain, psychometric variables, and analgesic consumption during inpatient interdisciplinary multimodal pain therapy (IMPT)"],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s00482-023-00727-4","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Bettstetter erhielt pers\u00f6nliche Honorare von TEVA GmbH und Apurano Pharmaceuticals GmbH au\u00dferhalb der eingereichten Arbeit. A.\u00a0Sch\u00e4fer erhielt pers\u00f6nliche Honorare von Amgen, AstraZeneca, Novo Nordisk Pharma GmbH, au\u00dferhalb der eingereichten Arbeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}